J. Safra Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

J. Safra Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.4K	Sell	222 -46	-17%	-$2.55K	﹤0.01%	372
2026 Q1	$15.6K	Buy	268 +181	+208%	+$8.34K	﹤0.01%	332
2025 Q4	$3.9K	Hold	87	–	–	﹤0.01%	463
2025 Q3	$3.49K	Hold	87	–	–	﹤0.01%	337
2025 Q2	$2.72K	Buy	87 +3	+4%	+$98	﹤0.01%	337
2025 Q1	$2.82K	Buy	84 +73	+664%	+$2.77K	﹤0.01%	318
2024 Q4	$424	Hold	11	–	–	﹤0.01%	327
2024 Q3	$425	Buy	+11	New	+$444	﹤0.01%	287

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

J. Safra Asset Management's XENE Position: Q2 2026 in Review

J. Safra Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 17% in Q2 2026, selling an estimated $2.55K and leaving 222 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #372.

J. Safra Asset Management first reported a position in XENE in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.6K in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

J. Safra Asset Management held 222 shares of Xenon Pharmaceuticals worth $13.4K as of Q2 2026.
J. Safra Asset Management sold 46 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.55K.
Xenon Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #372 holding.
J. Safra Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
J. Safra Asset Management's Xenon Pharmaceuticals position peaked at $15.6K in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.